Oxford BioDynamics PLC

Commercializing EpiSwitch® 3D gene regulation for precision medicine

Oxford Biodynamics' portfolio of clinical smart tests based on EpiSwitch® technology aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare.

What sets us apart

episwitch_pse_logo.png

Detect prostate cancer likelihood from blood with 94% accuracy

An effective prostate cancer detection test that identifies an individual’s current likelihood of prostate cancer from blood. PSE is administered alongside or following a standard PSA test to significantly boost detection performance and reduce the number of men referred for unnecessary biopsies and treatments.

This powerful test is valuable for identifying individuals requiring biopsy and those suitable for active surveillance without further testing.

Learn more about EpiSwitch PSE

A leap forward in treating cancer

A first-of-its-kind blood test to provide guidance on navigating the toughest challenges associated with use of an essential, widely-used class of cancer therapies: Immune Checkpoint Inhibitors.

Now every patient can benefit from the world’s first test to assess the probability of therapeutic success of checkpoint inhibitor therapy with high accuracy.

Learn More about EpiSwitch CiRT

EpiSwitchMECFS_comingSoonLogo.png

A breakthrough first-in-class test for Myalgic Encephalomyelitis

For the first time, a simple blood test reliably identifies Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). In development, EpiSwitch ME/CFS demonstrated 96% accuracy in detecting the condition. For the millions of patients worldwide who have faced years of uncertainty, misdiagnosis, or dismissal with this often-debilitating illness, EpiSwitch ME/CFS offers hope for faster, more reliable diagnosis.

Powered by OBD’s EpiSwitch 3D genomics platform, this breakthrough not only enables accurate testing but also advances understanding of the disease’s biological mechanisms, supporting development of targeted therapies and clinical trials.

Read our ME/CFS press release Read the peer-reviewed publication

EpiSwitchOrion_logo.png

Unlocking hidden clinical insight from complex genomic data

A high-resolution 3D genomics tool that uses basic DNA sequence to reveal how changes in the genome could affect health and disease. Orion looks at the genome’s regulatory “dark matter” to reveal how changes in DNA sequence affect the 3D structure, which can turn genes on or off, giving deeper insight into disease and treatment response.

Powered by EpiSwitch AI algorithms and an integrated Knowledge Graph, Orion helps researchers and drug developers identify disease-driving targets, more accurately stratify patients, and accelerate precision medicine across many diseases.

Learn more about EpiSwitch Orion

Vast, previously untapped data critical for health unlocked by the EpiSwitch platform

Enabling 3D genomics for precision medicine at scale

The EpiSwitch platform is uniquely capable of reproducibly translating 3D genome regulation for clinical application.

Explore our technology

In The News

To view and search our latest featured news, visit our in the news page.

View news